Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary (25) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Orphan designations Remove Orphan designations filter Referrals Remove Referrals filter Summaries of opinion (6) Apply Summaries of opinion filter Withdrawn applications (26) Apply Withdrawn applications filter Direct healthcare professional communication (2) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (4) Apply Yes filter

Authorisation status

Authorised (296) Apply Authorised filter Refused (3) Apply Refused filter Withdrawn (51) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (1) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (5) Apply PM: decision on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

Orphan disease / condition

Orphan decision number

Orphan designation status

Positive (18) Apply Positive filter

Referral name

Referral status

European Commission final decision (4) Apply European Commission final decision filter

Referral safety status

Yes (2) Apply Yes filter

Referral type

Article 31 referrals (4) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CHMP-EC (4) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (4) Apply Centrally and nationally authorised products (mixed) filter

Referral PRAC recommendation

Risk minimisation measures (2) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Biosimilar Remove Biosimilar filter Exceptional circumstances Remove Exceptional circumstances filter Generic Remove Generic filter Accelerated assessment (99) Apply Accelerated assessment filter Additional monitoring (630) Apply Additional monitoring filter Conditional approval (75) Apply Conditional approval filter Orphan medicine (399) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

379 results

Remove all filtersRemove all filters

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Orphan designations Remove Orphan designations filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter

Categories Human Remove Human filter

Medicine type Exceptional circumstances Remove Exceptional circumstances filter Generic Remove Generic filter Biosimilar Remove Biosimilar filter

Sort by

List item

Human medicine European public assessment report (EPAR): Firdapse (previously Zenas) (updated)

amifampridine, Lambert-Eaton Myasthenic Syndrome
Date of authorisation: 23/12/2009, , , Revision: 19, Authorised, Last updated: 25/09/2020
List item

Human medicine European public assessment report (EPAR): Fulvestrant Mylan (updated)

fulvestrant, Breast Neoplasms
Date of authorisation: 08/01/2018, , Revision: 3, Authorised, Last updated: 24/09/2020
List item

Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria) (updated)

insulin glargine, Diabetes Mellitus
Date of authorisation: 09/09/2014, , Revision: 9, Authorised, Last updated: 23/09/2020
List item

Human medicine European public assessment report (EPAR): Strensiq (updated)

asfotase alfa, Hypophosphatasia
Date of authorisation: 28/08/2015, , , , Revision: 13, Authorised, Last updated: 21/09/2020
List item

Human medicine European public assessment report (EPAR): Pemetrexed medac (updated)

pemetrexed, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Date of authorisation: 26/11/2015, , Revision: 6, Authorised, Last updated: 21/09/2020
List item

Human medicine European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Mylan (updated)

acetylsalicylic acid, clopidogrel hydrogen sulfate, Acute Coronary Syndrome, Myocardial Infarction
Date of authorisation: 09/01/2020, , Revision: 1, Authorised, Last updated: 21/09/2020
List item

Human medicine European public assessment report (EPAR): Voriconazole Hikma (previously Voriconazole Hospira) (updated)

voriconazole, Bacterial Infections and Mycoses, Aspergillosis, Candidiasis
Date of authorisation: 27/05/2015, , Revision: 8, Authorised, Last updated: 21/09/2020
List item

Human medicine European public assessment report (EPAR): Sildenafil Actavis (updated)

sildenafil, Erectile Dysfunction
Date of authorisation: 10/12/2009, , Revision: 13, Authorised, Last updated: 18/09/2020
List item

Human medicine European public assessment report (EPAR): Ruxience (updated)

rituximab, Leukemia, Lymphocytic, Chronic, B-Cell, Arthritis, Rheumatoid, Microscopic Polyangiitis, Pemphigus
Date of authorisation: 01/04/2020, , , Revision: 2, Authorised, Last updated: 17/09/2020
List item

Human medicine European public assessment report (EPAR): Bortezomib Sun (updated)

bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016, , Revision: 8, Authorised, Last updated: 17/09/2020
List item

Human medicine European public assessment report (EPAR): Arsenic trioxide Accord (updated)

Arsenic trioxide, Leukemia, Promyelocytic, Acute
Date of authorisation: 14/11/2019, , Revision: 2, Authorised, Last updated: 16/09/2020
List item

Human medicine European public assessment report (EPAR): Tolura (updated)

telmisartan, Hypertension
Date of authorisation: 04/06/2010, , Revision: 9, Authorised, Last updated: 16/09/2020
List item

Human medicine European public assessment report (EPAR): Azacitidine Mylan (updated)

azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 27/03/2020, , Revision: 1, Authorised, Last updated: 16/09/2020
List item

Human medicine European public assessment report (EPAR): Ebilfumin (updated)

oseltamivir, Influenza, Human
Date of authorisation: 22/05/2014, , Revision: 12, Authorised, Last updated: 16/09/2020
List item

Human medicine European public assessment report (EPAR): Desloratadine Teva (updated)

desloratadine, Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal
Date of authorisation: 24/11/2011, , Revision: 15, Authorised, Last updated: 16/09/2020
List item

Human medicine European public assessment report (EPAR): Pioglitazone Actavis (updated)

pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2012, , Revision: 7, Authorised, Last updated: 16/09/2020
List item

Human medicine European public assessment report (EPAR): Cinacalcet Mylan (updated)

cinacalcet hydrochloride, Hyperparathyroidism, Secondary, Hypercalcemia
Date of authorisation: 19/11/2015, , Revision: 7, Authorised, Last updated: 14/09/2020
List item

Human medicine European public assessment report (EPAR): Leflunomide ratiopharm (updated)

leflunomide, Arthritis, Rheumatoid
Date of authorisation: 28/11/2010, , Revision: 14, Authorised, Last updated: 11/09/2020
List item

Human medicine European public assessment report (EPAR): Imatinib Accord (updated)

imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dermatofibrosarcoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome
Date of authorisation: 30/06/2013, , Revision: 16, Authorised, Last updated: 11/09/2020
List item

Human medicine European public assessment report (EPAR): Imatinib Actavis (updated)

imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Hypereosinophilic Syndrome, Dermatofibrosarcoma
Date of authorisation: 17/04/2013, , Revision: 12, Authorised, Last updated: 10/09/2020
List item

Human medicine European public assessment report (EPAR): Pramipexole Accord (updated)

pramipexole dihydrochloride monohydrate, Parkinson Disease, Restless Legs Syndrome
Date of authorisation: 29/09/2011, , Revision: 9, Authorised, Last updated: 09/09/2020
List item

Human medicine European public assessment report (EPAR): Ibandronic Acid Teva (updated)

ibandronic acid, Breast Neoplasms, Neoplasm Metastasis, Fractures, Bone, Osteoporosis, Postmenopausal
Date of authorisation: 17/09/2010, , Revision: 9, Authorised, Last updated: 09/09/2020
List item

Human medicine European public assessment report (EPAR): Temomedac (updated)

temozolomide, Glioma, Glioblastoma
Date of authorisation: 25/01/2010, , Revision: 14, Authorised, Last updated: 09/09/2020
List item

Human medicine European public assessment report (EPAR): Erelzi (updated)

etanercept, Arthritis, Psoriatic, Psoriasis, Arthritis, Juvenile Rheumatoid, Arthritis, Rheumatoid, Spondylitis, Ankylosing
Date of authorisation: 23/06/2017, , , Revision: 7, Authorised, Last updated: 08/09/2020
List item

Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi (updated)

bortezomib, Multiple Myeloma
Date of authorisation: 14/11/2019, , Revision: 2, Authorised, Last updated: 07/09/2020

Load more

379 results

Human medicine European public assessment report (EPAR): Firdapse (previously Zenas) (updated)

Human medicine European public assessment report (EPAR): Fulvestrant Mylan (updated)

Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria) (updated)

Human medicine European public assessment report (EPAR): Strensiq (updated)

Human medicine European public assessment report (EPAR): Pemetrexed medac (updated)

Human medicine European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Mylan (updated)

Human medicine European public assessment report (EPAR): Voriconazole Hikma (previously Voriconazole Hospira) (updated)

Human medicine European public assessment report (EPAR): Sildenafil Actavis (updated)

Human medicine European public assessment report (EPAR): Ruxience (updated)

Human medicine European public assessment report (EPAR): Bortezomib Sun (updated)

Human medicine European public assessment report (EPAR): Arsenic trioxide Accord (updated)

Human medicine European public assessment report (EPAR): Tolura (updated)

Human medicine European public assessment report (EPAR): Azacitidine Mylan (updated)

Human medicine European public assessment report (EPAR): Ebilfumin (updated)

Human medicine European public assessment report (EPAR): Desloratadine Teva (updated)

Human medicine European public assessment report (EPAR): Pioglitazone Actavis (updated)

Human medicine European public assessment report (EPAR): Cinacalcet Mylan (updated)

Human medicine European public assessment report (EPAR): Leflunomide ratiopharm (updated)

Human medicine European public assessment report (EPAR): Imatinib Accord (updated)

Human medicine European public assessment report (EPAR): Imatinib Actavis (updated)

Human medicine European public assessment report (EPAR): Pramipexole Accord (updated)

Human medicine European public assessment report (EPAR): Ibandronic Acid Teva (updated)

Human medicine European public assessment report (EPAR): Temomedac (updated)

Human medicine European public assessment report (EPAR): Erelzi (updated)

Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi (updated)